These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25163980)

  • 1. Quantitative assessment of intestinal first-pass metabolism of oral drugs using portal-vein cannulated rats.
    Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
    Pharm Res; 2015 Feb; 32(2):604-16. PubMed ID: 25163980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explication of Definitional Description and Empirical Use of Fraction of Orally Administered Drugs Absorbed From the Intestine (Fa) and Intestinal Availability (Fg): Effect of P-glycoprotein and CYP3A on Fa and Fg.
    Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
    J Pharm Sci; 2016 Feb; 105(2):431-442. PubMed ID: 26869410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
    Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separate Evaluation of Fraction Absorbed and Intestinal Availability after Oral Administration of Drugs Based on the Measurement of Portal and Systemic Plasma Concentrations and Luminal Concentration.
    Tanaka Y; Ito K; Kurakazu T; Kasaoka S
    Mol Pharm; 2023 Apr; 20(4):1933-1941. PubMed ID: 36914610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism.
    Dufek MB; Knight BM; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Mar; 41(3):642-50. PubMed ID: 23288866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.
    Komura H; Iwaki M
    Drug Metab Rev; 2011 Nov; 43(4):476-98. PubMed ID: 21859377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
    Dufek MB; Bridges AS; Thakker DR
    Drug Metab Dispos; 2013 Sep; 41(9):1695-702. PubMed ID: 23821186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using single-pass intestinal perfusion.
    Takahashi M; Washio T; Suzuki N; Igeta K; Yamashita S
    Biol Pharm Bull; 2010; 33(1):111-6. PubMed ID: 20045946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method.
    Kadono K; Koakutsu A; Naritomi Y; Terashita S; Tabata K; Teramura T
    Xenobiotica; 2014 Jun; 44(6):511-21. PubMed ID: 24329478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats.
    Matsuda Y; Konno Y; Satsukawa M; Kobayashi T; Takimoto Y; Morisaki K; Yamashita S
    Drug Metab Dispos; 2012 Dec; 40(12):2231-8. PubMed ID: 22930277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism.
    Mudra DR; Borchardt RT
    J Pharm Sci; 2010 Feb; 99(2):982-98. PubMed ID: 19746412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
    Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
    J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development.
    Karlsson FH; Bouchene S; Hilgendorf C; Dolgos H; Peters SA
    Drug Metab Dispos; 2013 Dec; 41(12):2033-46. PubMed ID: 23918667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.
    Heikkinen AT; Baneyx G; Caruso A; Parrott N
    Eur J Pharm Sci; 2012 Sep; 47(2):375-86. PubMed ID: 22759901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats.
    Chiang TY; Wang HJ; Wang YC; Chia-Hui Tan E; Lee IJ; Yun CH; Ueng YF
    J Ethnopharmacol; 2021 May; 271():113914. PubMed ID: 33571617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys.
    Nishimuta H; Sato K; Mizuki Y; Yabuki M; Komuro S
    Drug Metab Dispos; 2010 Nov; 38(11):1967-75. PubMed ID: 20702772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential roles of P-glycoprotein, multidrug resistance-associated protein 2, and CYP3A on saquinavir oral absorption in Sprague-Dawley rats.
    Usansky HH; Hu P; Sinko PJ
    Drug Metab Dispos; 2008 May; 36(5):863-9. PubMed ID: 18256206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
    Suzuki K; Taniyama K; Aoyama T; Watanabe Y
    Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.